2131223-64-6
2131223-64-6
Chemical Structure
YW1128
- CAS No.: 2131223-64-6
- Formula:C20H17N5O
- Molecular Weight:343.38
IUPAC Name: 5-methyl-N-(quinolin-2-yl)-1-(o-tolyl)-1H-1,2,3-triazole-4-carboxamide
InChIKey: SXZFICNOPPNYJM-UHFFFAOYSA-N
SMILES: O=C(C1=C(C)N(C2=CC=CC=C2C)N=N1)NC3=NC4=CC=CC=C4C=C3
Biological Activity: YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
YW1128 | 99.38% | YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FPTQ | 99.92% | FPTQ is potent mGluR1 antagonist with IC50 values of 6 nM and 1.4 nM for human and mouse mGluR1 respectively. FPTQ has anti-oxidant and anti-inflammatory effects in vitro and in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DDX3-IN-1 | 99.67% | DDX3-IN-1 (Compound 16f) is the inhibitor for DEAD box polypeptide 3 (DDX3) with an IC50 >100 μM. DDX3-IN-1 exhibits antiviral activity against HIV and HCV. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Wnt/β-catenin-IN-4 | Wnt/β-catenin-IN-4 (compound YW1159) is a potent Wnt/β-catenin inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DNDI-6148 | 99.54% | DNDI-6148 is a novel preclinical candidate for the research of visceral leishmaniasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
YW2065 | 99.91% | YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of wnt/β-catenin signaling inhibition and AMPK activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mtb-IN-3 | Mtb-IN-3 (compound 10c) is an inhibitor of Mycobacterium tuberculosis (Mtb). Mtb-IN-3 shows selective, potent in vitro antimycobacterial activity without cytotoxicity. Mtb-IN-3 inhibits colony-forming in spleen in the murine tuberculosis model. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anticancer agent 83 | Anticancer agent 83 is a potent anticancer agent, inhibits LOX IMVI cells growth with a GI50 value of 0.15 mM. Anticancer agent 83 reduces mitochondrial membrane potential and induces DNA damage to induces leukemia cells apoptosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
YW2036 | 99.48% | YW2036 (compound 2a) is a potent Wnt/β-Catenin signaling pathway inhibitor with an IC50 value of 637 nM. YW2036 can be used in research of colorectal cancer (CRC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MJO445 | MJO445 (Compound 7) is a ATG4B inhibitor, which inhibits the autophagy of glioblastoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FB231 | 99.45% | FB231 is a Parkin activator. FB231 can induce mild mitochondrial stress, resulting in impaired mitochondrial function and activation of the integrated stress response. FB231 can lower the threshold for mitochondrial toxins to induce PINK1/Parkin-mediated mitophagy. FB231 can cause activation of the integrated stress response (ISR) and perturbation to iron-dependent pathways. FB231 can be used for the research of neurological disease, such as Parkinson’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
